InCarda

InCarda Therapeutics is developing a drug/device combination for in-hospital and outpatient treatment of acute atrial fibrillation. By using the pulmonary circulation to deliver drugs to the heart, lower doses and faster cardioversion are likely to occur compared to oral and intravenous therapies. The initial target market will be the in-hospital setting where most patients with atrial fibrillation currently require electrical cardioversion, an invasive and costly procedure.